SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Maartje N. Niemeijer, Marten E. van den Berg, Mark Eijgelsheim, Peter R. Rijnbeek, Bruno H. Stricker, Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update, Drug Safety, 2015,

    CrossRef

  2. 2
    Dennis Kelleher, Lee Tombs, Andrew Preece, Noushin Brealey, Rashmi Mehta, A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects, Pulmonary Pharmacology & Therapeutics, 2014, 29, 1, 49

    CrossRef

  3. 3
    Marek Malik, Katerina Hnatkova, Donna Kowalski, James J. Keirns, E. Marcel van Gelderen, Have individual QT/RR curvatures value in QT correction?, Journal of Electrocardiology, 2014, 47, 3, 386

    CrossRef

  4. 4
    Lars Johannesen, Christine Garnett, Marek Malik, Impact of Electrocardiographic Data Quality on Moxifloxacin Response in Thorough QT/QTc Studies, Drug Safety, 2014, 37, 3, 183

    CrossRef

  5. 5
    Jorg Taubel, Georg Ferber, Ulrike Lorch, Velislav Batchvarov, Irina Savelieva, A. John Camm, Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects, British Journal of Clinical Pharmacology, 2014, 77, 1
  6. 6
    Rashmi R. Shah, Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?, British Journal of Clinical Pharmacology, 2013, 75, 2
  7. 7
    Rashmi R. Shah, Joel Morganroth, ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies, British Journal of Clinical Pharmacology, 2013, 75, 4
  8. 8
    Raymundo Cassani González, Elien B. Engels, Bruno Dubé, Réginald Nadeau, Alain Vinet, A. Robert LeBlanc, Marcio Sturmer, Giuliano Becker, Teresa Kus, Vincent Jacquemet, Assessment of the sensitivity of detecting drug-induced QTc changes using subject-specific rate correction, Journal of Electrocardiology, 2012, 45, 6, 541

    CrossRef

  9. 9
    Alessandra Pugi, Loreta Longo, Alessandro Bartoloni, Gian Maria Rossolini, Alessandro Mugelli, Alfredo Vannacci, Francesco Lapi, Cardiovascular and metabolic safety profiles of the fluoroquinolones, Expert Opinion on Drug Safety, 2012, 11, 1, 53

    CrossRef

  10. 10
    R. Thertulien, G. M. Manikhas, L. Y. Dirix, J. B. Vermorken, K. Park, M. M. Jain, J. J. Jiao, J. Natarajan, T. Parekh, P. Zannikos, A. P. Staddon, Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies, Cancer Chemotherapy and Pharmacology, 2012, 69, 2, 341

    CrossRef

  11. 11
    Norman Stockbridge, Joanne Zhang, Christine Garnett, Marek Malik, Practice and challenges of thorough QT studies, Journal of Electrocardiology, 2012, 45, 6, 582

    CrossRef

  12. 12
    Marek Malik, Joanne Zhang, Lars Johannesen, Katerina Hnatkova, Christine Garnett, Assessing electrocardiographic data quality and possible replacement of pharmacologic positive control in thorough QT/QTc studies by investigations of drug-free QTc stability, Heart Rhythm, 2011, 8, 11, 1777

    CrossRef

  13. 13
    Kenny J. Watson, William P. Gorczyca, John Umland, Ying Zhang, Xian Chen, Sunny Z. Sun, Bernard Fermini, Mark Holbrook, Piet H. Van Der Graaf, Pharmacokinetic–pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys, Journal of Pharmacological and Toxicological Methods, 2011, 63, 3, 304

    CrossRef

  14. 14
    Jeffry A. Florian, Christoffer W. Tornøe, Richard Brundage, Ameeta Parekh, Christine E. Garnett, Population Pharmacokinetic and Concentration—QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies, The Journal of Clinical Pharmacology, 2011, 51, 8
  15. 15
    Martin K Church, Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria, Expert Opinion on Drug Safety, 2011, 10, 5, 779

    CrossRef

  16. 16
    Eathar Razak, Marie Buncová, Vladimir Shusterman, Bruce Winter, Win-Kuang Shen, Michael J. Ackerman, Theresa Donovan, Rachel Lampert, Jan Němec, Slow QT Interval Adaptation to Heart Rate Changes in Normal Ambulatory Subjects, Annals of Noninvasive Electrocardiology, 2011, 16, 2
  17. 17
    Andreas Huennemeyer, Nassr Nassr, Dirk Bredenbröker, Gezim Lahu, Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects, Expert Opinion on Drug Safety, 2011, 10, 4, 509

    CrossRef

  18. 18
    Marek Malik, Does the Prulifloxacin ECG Study Prove Cardiac Safety of the Drug?, Clinical Drug Investigation, 2010, 30, 1, 1

    CrossRef

  19. 19
    Marek Malik, Facts, fancies and follies of drug-induced QT/QTc interval shortening, British Journal of Pharmacology, 2010, 159, 1
  20. 20
    Hartmut Lode, Safety and Tolerability of Commonly Prescribed Oral Antibiotics for the Treatment of Respiratory Tract Infections, The American Journal of Medicine, 2010, 123, 4, S26

    CrossRef

  21. 21
    Marek Malik, Christine E. Garnett, Joanne Zhang, Thorough QT Studies, Drug Safety, 2010, 33, 1, 1

    CrossRef